270 related articles for article (PubMed ID: 36394204)
1. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.
Yuan X; Liu T; Xu D
Ann Transl Med; 2020 Oct; 8(19):1244. PubMed ID: 33178776
[TBL] [Abstract][Full Text] [Related]
3. Telomerase and Telomeres Biology in Thyroid Cancer.
Donati B; Ciarrocchi A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200515
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
5.
Liu T; Li S; Xia C; Xu D
Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
[TBL] [Abstract][Full Text] [Related]
6. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
7. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
9. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.
Wang N; Xu D; Sofiadis A; Höög A; Vukojević V; Bäckdahl M; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1571-9. PubMed ID: 24758186
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
11. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
12. Regulation of telomere length and homeostasis by telomerase enzyme processivity.
D'Souza Y; Lauzon C; Chu TW; Autexier C
J Cell Sci; 2013 Jan; 126(Pt 2):676-87. PubMed ID: 23178942
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.
Montero-Conde C; Leandro-García LJ; Martínez-Montes ÁM; Martínez P; Moya FJ; Letón R; Gil E; Martínez-Puente N; Guadalix S; Currás-Freixes M; García-Tobar L; Zafon C; Jordà M; Riesco-Eizaguirre G; González-García P; Monteagudo M; Torres-Pérez R; Mancikova V; Ruiz-Llorente S; Pérez-Martínez M; Pita G; Galofré JC; Gonzalez-Neira A; Cascón A; Rodríguez-Antona C; Megías D; Blasco MA; Caleiras E; Rodríguez-Perales S; Robledo M
Clin Transl Med; 2022 Aug; 12(8):e1001. PubMed ID: 35979662
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
[TBL] [Abstract][Full Text] [Related]
16. Downregulation and Hypermethylation of GABPB1 Is Associated with Aggressive Thyroid Cancer Features.
Xing X; Mu N; Yuan X; Wang N; Juhlin CC; Strååt K; Larsson C; Neo SY; Xu D
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326537
[TBL] [Abstract][Full Text] [Related]
17. TERT Promoter Mutations in Thyroid Cancer.
Alzahrani AS; Alsaadi R; Murugan AK; Sadiq BB
Horm Cancer; 2016 Jun; 7(3):165-77. PubMed ID: 26902827
[TBL] [Abstract][Full Text] [Related]
18. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
20. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.
Tahara I; Oishi N; Mochizuki K; Oyama T; Miyata K; Miyauchi A; Hirokawa M; Katoh R; Kondo T
Endocr Pathol; 2020 Sep; 31(3):274-282. PubMed ID: 32594366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
